Crucial Areas on AF Termination

March 28, 2014 updated by: SEITZ JULIEN, Hospital St. Joseph, Marseille, France

Crucial Areas on Atrial Fibrillation Termination by Substrate Ablation: Relevance to Anatomy

Recent data has demonstrated that focal sources are determinant in human atrial fibrillation (AF) perpetuation.

The investigators sought to identify crucial areas for AF perpetuation during our routine electrogram (EGM)-based substrate ablation.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

113

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Marseille, France, 13008
        • Hopital Saint Joseph
      • Massy, France
        • Hôpital Privé Jacques Cartier;
      • Paris, France
        • Institut Mutualiste Montsouris;
  • United Kingdom
      • London;, United Kingdom
        • Morphology Unit Royal Brompton Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with symptomatic Atrial Fibrilation undergoing EGM-based substrate ablation were included.

Description

Inclusion Criteria:

  • Atrial Fibrilation
  • Undergoing EGM-based substrate ablation

Exclusion Criteria:

  • Age < 18

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Atria fibrillation termination during procedure
Time Frame: 240 min
conversion to atrial tachycardia (AT) or sinus rhythm
240 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Crucial points
Time Frame: 240 min
Crucial points were defined by areas where ablation immediately extended the cycle length> 20% of AF CL, or regularized Atrial Fibrilation (AF) into Atrial Tachycardia (AT) or converted AF (or AT) into Sinus Rythm
240 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital St. Joseph, Marseille, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2008

Primary Completion (Actual)

March 1, 2014

Study Completion (Actual)

March 1, 2014

Study Registration Dates

First Submitted

March 26, 2014

First Submitted That Met QC Criteria

March 28, 2014

First Posted (Estimate)

March 31, 2014

Study Record Updates

Last Update Posted (Estimate)

March 31, 2014

Last Update Submitted That Met QC Criteria

March 28, 2014

Last Verified

March 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • HSJ-2013-03

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrilation Termination Endpoint

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe